Literature DB >> 21682951

Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease.

Tae Ho Lee1, Lucia Pastorino, Kun Ping Lu.   

Abstract

Phosphorylation of proteins on serine or threonine residues preceding proline is a key signalling mechanism in diverse physiological and pathological processes. Pin1 (peptidyl-prolyl cis-trans isomerase) is the only enzyme known that can isomerise specific Ser/Thr-Pro peptide bonds after phosphorylation and regulate their conformational changes with high efficiency. These Pin1-catalysed conformational changes can have profound effects on phosphorylation signalling by regulating a spectrum of target activities. Interestingly, Pin1 deregulation is implicated in a number of diseases, notably ageing and age-related diseases, including cancer and Alzheimer disease. Pin1 is overexpressed in most human cancers; it activates numerous oncogenes or growth enhancers and also inactivates a large number of tumour suppressors or growth inhibitors. By contrast, ablation of Pin1 prevents cancer, but eventually leads to premature ageing and neurodegeneration. Consistent with its neuroprotective role, Pin1 has been shown to be inactivated in neurons of patients with Alzheimer disease. Therefore, Pin1-mediated phosphorylation-dependent prolyl isomerisation represents a unique signalling mechanism that has a pivotal role in the development of human diseases, and might offer an attractive new diagnostic and therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21682951     DOI: 10.1017/S1462399411001906

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  74 in total

1.  Death-associated protein kinase 1 phosphorylates NDRG2 and induces neuronal cell death.

Authors:  Mi-Hyeon You; Byeong Mo Kim; Chun-Hau Chen; Michael J Begley; Lewis C Cantley; Tae Ho Lee
Journal:  Cell Death Differ       Date:  2016-11-04       Impact factor: 15.828

2.  Differential regulation of cellular senescence and differentiation by prolyl isomerase Pin1 in cardiac progenitor cells.

Authors:  Haruhiro Toko; Nirmala Hariharan; Mathias H Konstandin; Lucia Ormachea; Michael McGregor; Natalie A Gude; Balaji Sundararaman; Eri Joyo; Anya Y Joyo; Brett Collins; Shabana Din; Sadia Mohsin; Takafumi Uchida; Mark A Sussman
Journal:  J Biol Chem       Date:  2013-12-27       Impact factor: 5.157

3.  The cellular peptidyl-prolyl cis/trans isomerase Pin1 regulates reactivation of Kaposi's sarcoma-associated herpesvirus from latency.

Authors:  Jonathan Guito; Aileen Gavina; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

4.  B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells.

Authors:  Frank Secreto; Michelle Manske; Tammy Price-Troska; Steven Ziesmer; Lucy S Hodge; Stephen M Ansell; James R Cerhan; Anne J Novak
Journal:  Leuk Lymphoma       Date:  2014-02-24

Review 5.  Landscape of Pin1 in the cell cycle.

Authors:  Cheng-Han Lin; Hao-Yi Li; Yu-Cheng Lee; Marcus J Calkins; Kuen-Haur Lee; Chia-Ning Yang; Pei-Jung Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-07

Review 6.  Determinants of eosinophil survival and apoptotic cell death.

Authors:  Zhong-Jian Shen; James S Malter
Journal:  Apoptosis       Date:  2015-02       Impact factor: 4.677

7.  An unusual two-step control of CPEB destruction by Pin1.

Authors:  Morris Nechama; Chien-Ling Lin; Joel D Richter
Journal:  Mol Cell Biol       Date:  2012-10-22       Impact factor: 4.272

8.  The prolyl isomerase Pin1 targets stem-loop binding protein (SLBP) to dissociate the SLBP-histone mRNA complex linking histone mRNA decay with SLBP ubiquitination.

Authors:  Nithya Krishnan; Tukiet T Lam; Andrew Fritz; Donald Rempinski; Kieran O'Loughlin; Hans Minderman; Ronald Berezney; William F Marzluff; Roopa Thapar
Journal:  Mol Cell Biol       Date:  2012-08-20       Impact factor: 4.272

9.  Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.

Authors:  Chandraiah Godugu; Ravi Doddapaneni; Apurva R Patel; Rakesh Singh; Roger Mercer; Mandip Singh
Journal:  Pharm Res       Date:  2015-08-19       Impact factor: 4.200

10.  Cis phosphorylated tau as the earliest detectable pathogenic conformation in Alzheimer disease, offering novel diagnostic and therapeutic strategies.

Authors:  Kazuhiro Nakamura; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Prion       Date:  2012-11-15       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.